6C.V. liew. The influence of operational variables on mean size and size distribution of spheroids produced by rotary spheronization[J]. International Journal of Pharmaceutics, 2002,242:345.
3Khanna I. Drug discovery in pharmaceutical indus try: productivity challenges and trends[J]. Drug Diseov Today, 2012, 17(19/20) :1088-1102.
4Wahlqvist ML, Lee MS, Chuang SY, et al. In- creased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combi- nation: a population-based cohort study [J].BMC Med, 2012, 10(1):150.
5Xu TJ, Yuan BX, Zou YM, et al. The effect of in sulin in combination with selenium on blood glucose and GLUT4 expression in the cardiac muscle of streptozotocin-induced diabetic rats[J].Fundam ClinPharmacol, 2010, 24(2):199 -204.
6Trottier B, Machouf N, Thomas R, et al. Aba cavir/lamivudine fixed-dose combination with ritonavir boosted darunavir: a safe and efficacious regimen for HIV therapy [J]. HIV Clin Trials,2012, 13(6):335- 342.
7Ward D, Grant R. Rilpivirine/tenofovir/emtricit- abine fixed dose combination is an efficacious and well tolerated " switch" regimen for patients on therapy [J]. J Int AIDSSoc, 2012, 15(6):18351.
8Inoue M. Tighter control of postprandial hypergly- cemia with mitiglinide/voglibose fixed-dose combi nation in Japanese patients with type 2 diabetes mel litus [J]. Expert Opin Pharmacother, 2012, 13 (16) :2257-2268.
9Williams SA, Buysman EK, Hulbert EM, et al. Hemoglobin Alc outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose dose and fixed dose combinations [J]. ManagCare, 2012, 21(7) :40-48.
10Kjeldsen SE, Messerli FH, Chiang CE, et al. Are fixed-dose combination antihypertensives suitable as first fine therapy [J].? Curr Med Res Opin, 2012, 28(10) :1685-1697.
